77 results about "Insulin delivery" patented technology

A method may include obtaining blood glucose level readings over a diurnal period for each of a plurality of days and determining an estimated variability of the blood glucose levels over the diurnal period for the plurality of days. The method may also include modifying, based on the estimated variability of the blood glucose level, a target blood glucose level to a modified target blood glucose level, and delivering insulin, using an insulin pump, during the diurnal period based on the modified target blood glucose level.

In an infusion pump system that includes a pump that may have a user interface for pump programming, one or more smartphones or other remote control devices that interface with the infusion pump, and / or an automated insulin delivery algorithm, there is a potential conflict between commands such as boluses being programmed on multiple devices and / or calculated by the AID algorithm at the same time. In order to avoid low glucose levels that could result from delivering multiple boluses from these various sources when only one bolus is needed, systems and methods disclosed herein provide a bolus permissions and prioritization scheme that prioritizes boluses programmed with the infusion pump and one or more remote control devices and calculated by a closed loop delivery algorithm.

Disclosed herein are apparatuses and methods that can provide a delayed bolus calculator for use in closed loop diabetes therapy that can account for additional factors not taken into account in regular meal bolus calculations when a user wants to deliver a meal bolus a period of time after a meal was consumed. A delayed bolus calculator can enable the user to enter a period of time since the meal was consumed in addition to the number of carbohydrates consumed in a meal. This enables the system to account for the amount of increased insulin from the closed loop algorithm in response to the meal and / or the time since the meal to ensure that the risk of hypoglycemia is mitigated while still reducing hyperglycemia.

A method may include obtaining blood glucose level readings over a diurnal period for each of a plurality of days and determining an estimated variability of the blood glucose levels over the diurnal period for the plurality of days. The method may also include modifying, based on the estimated variability of the blood glucose level, a target blood glucose level to a modified target blood glucose level, and delivering insulin, using an insulin pump, during the diurnal period based on the modified target blood glucose level.

An automated insulin delivery system provides an insulin injection that is computed by adding (i) the recommendation of an artificial neural network trained to mimic a constrained model predictive controller dosing rule from a neural network implementing an artificial pancreas (ii) a hypoglycemia mitigation system includeds a correction (one dose computed as the correction down to 110mg / dl based on prevailing continuous glucose monitoring and once an hour at most, unless there is a triggering BPS and G>180 mg / dl), and (iii) the current basal rate (output of the Performance Assessment System, (PAS)); that amount is then saturated by the Safety Supervision System, SSM. Finally, a priming bolus from the Bolus Priming System, BPS, is added to the total if the conditions for large glycemic excursions are detected, also saturated by SSM.

The invention discloses application of low-esterification pectin in preparation of intelligent nanoparticles for oral delivery of insulin. The application comprises preparation of pectin with different esterification degrees, subcritical water treatment of pectin and preparation of pectin-based intelligent nanoparticles. According to the invention, through esterification degree regulation and control of pectin, a subcritical water treatment process and use of appropriate auxiliary materials, the embedding efficiency of insulin and the stability of nanoparticles are remarkably improved, the degradation of insulin in a gastrointestinal tract environment is reduced, and the oral bioavailability of drugs is improved.

Techniques disclosed herein related to controlling insulin delivery. In some embodiments, the techniques may involve delivering insulin via an insulin infusion device according to a closed-loop mode of delivery. The techniques may further involve determining, at a first time point, insulin delivery is to be switched from the closed-loop mode of delivery to a second mode of delivery. The techniques may further involve switching operation of the insulin infusion device to the second mode of delivery such that insulin is delivered via the insulin infusion device according to the second mode of delivery.

A diabetes management system optimizes glucoregulatory hormone delivery using a connected glucoregulatory hormone delivery system and a computing device with a processor and non-transitory memory. The system receives glucose management data (glucose, insulin delivery, heart rate, or carbohydrate consumption data) from sensors. A digital twin metabolic model is selected and initialized based on the received data. The system simulates diabetes treatment interventions to predict glucose dynamics and determines an optimized glucoregulatory hormone parameter (e.g., insulin dose or increment that minimizes hyperglycemia and hypoglycemia risk). The determined glucoregulatory hormone parameter is transmitted to the connected glucoregulatory hormone delivery system, which may include an automated insulin delivery (AID) system or a connected insulin pen system, for implementation. By integrating real-time physiological data with predictive metabolic modeling, the system enhances glucoregulatory hormone therapy, providing personalized adjustments to improve glucose control.

The invention belongs to the technical field of medical biological dressings, and provides a composite dressing with oxygen release and insulin delivery functions and a preparation method thereof.The composite dressing comprises a supporting base layer, a function slow release layer and a protective film layer which are sequentially compounded from bottom to top; the supporting base layer is a medical porous polyurethane film modified by plasma; the functional sustained release layer is composed of hyaluronic acid-chitosan composite gel, oxygen release microspheres and insulin liposome; the protective film layer is a polyethylene terephthalate film of which the surface is provided with a sawtooth edge easy to tear; through an integrated three-layer patch structure, by combining the synergistic effect of PLGA microsphere controlled-release oxygen, liposome low-molecular chitosan insulin delivery and gel matrix, the skin injury microenvironment is effectively improved, inflammation is inhibited, and the healing time is shortened.

The invention belongs to the field of drug delivery, and particularly relates to a glucose and ketone body dual-response long-acting insulin delivery system as well as a preparation method and application thereof. The glucose and ketone body dual-response long-acting insulin delivery system provided by the invention comprises a drug crystal, a polymer coating wrapping the drug crystal and a phenylboronic acid based cationic polymer modified in the polymer coating. The long-acting insulin can prolong the treatment time of the glucose-responsive insulin delivery carrier, meanwhile, the glucose-responsive insulin delivery carrier has a ketone body response behavior, ketoacidosis is inhibited, and the problems that an existing glucose-responsive insulin delivery carrier is short in treatment time, a ketone body-responsive insulin delivery carrier is difficult to construct and the like are solved.

An insulin delivery system for diabetes management includes a patch-based insulin pump configured to deliver insulin to a user, a user input button disposed on the patch-based insulin pump, a processor configured to execute a hybrid closed loop algorithm that automatically controls insulin delivery based on glucose levels. The user input button is configured to receive user input comprising a sequence of button presses that communicate contextual information about user activities to the hybrid closed loop algorithm, the contextual information being distinct from direct insulin bolus delivery commands. The contextual information may include meal intake, physical activity, and sleep status communicated through different sequences of button presses. The system includes confirmation mechanisms that provide feedback and allow cancellation of inputs, enabling discrete real-time communication of personalized data to enhance diabetes management.

A simplified insulin pump allows diabetics to identify routine patterns in their daily lifestyle that provide a generally accurate typical pattern of activity and meals. An infusion regimen can be programmed into the pump that generally correlates with this typical pattern to provide a viable treatment option for a diabetic without the need for specific and precise matching of insulin to carbohydrate consumption or activity level.

The application discloses a glucose-responsive insulin delivery system and a preparation method and application thereof, and belongs to the technical field of biomaterials. The glucose-responsive insulin delivery system provided by the application comprises a delivery carrier and a bioactive component encapsulated in the carrier; the delivery carrier is a metal polyphenol network formed by a coordination reaction between epigallocatechin gallate and metal ions; and the bioactive component comprises glucose oxidase, catalase and insulin. The glucose-responsive insulin delivery system can adjust the release of insulin according to the concentration of glucose in the surrounding environment, so that the blood glucose can be maintained at a normal level.

Disclosed are techniques, devices and systems that obtain a glucose measurement history and a liquid drug delivery history. An expected drug delivery amount may be calculated based on the obtained glucose measurement history and the obtained liquid drug delivery history. A processor may calculate a plurality of respective drug delivery amounts implemented using different advisory mode algorithms. A respective advisory drug delivery amount of the plurality of respective advisory drug delivery amounts may be selected by the processor. A recommendation may be generated based on the selected respective advisory drug delivery amount.

The invention relates to the technical field of biomedical engineering, and particularly discloses a portable insulin administration device which comprises a noninvasive blood glucose detection module, an insulin administration module, an insulin administration module and an insulin administration module which are sequentially arranged from bottom to top, and the noninvasive blood glucose detection module is used for monitoring the blood glucose concentration of a human body based on a counter-ion electroosmosis technology; the drug loading module is used for loading drugs, and the drugs comprise insulin; the transdermal drug delivery module is connected with the drug carrying module and used for applying pulse voltage to the skin to enhance the transdermal permeation efficiency of the skin when the monitored blood glucose concentration value is larger than a preset threshold value and driving the drug in the drug carrying module to permeate into the corium layer. The equipment monitors the blood sugar concentration of a human body in real time by adopting a counter-ion electroosmosis technology, realizes transdermal delivery of insulin through an electroporation technology, combines two functions of blood sugar concentration monitoring and insulin delivery, realizes integrated closed-loop control of symptom diagnosis and treatment, and can realize the two functions in a completely non-invasive manner, so that the operation is simple and convenient. The skin of a patient is not damaged.

A method of improving insulin delivery includes detecting a dosing event of an upcoming insulin dose, identifying a next injection site to recommend to a user for the upcoming insulin dose, and transmitting a recommended injection site to a delivery device to be displayed on the delivery device. The method further includes receiving a user selection of a plurality of injection sites to include within an injection site recommendation profile, receiving a user selection of an injection cycle to utilize within the injection site recommendation profile, and generating an injection site recommendation profile.

Systems and methods are disclosed for managing a person's blood glucose concentration within a predetermined range by co-administration of insulin and pramlintide using an automated insulin delivery system. A model predictive control (MPC) algorithm that includes a glucoregulatory control model augmented with a compartment model of pramlintide pharmacokinetics and pharmacodynamics is utilized. In some embodiments, the person may announce in advance meals to be consumed and the pramlintide-aware MPC algorithm uses this data as input to the glucoregulatory control model. In other embodiments, an automatic meal detection and size estimation algorithm is incorporated into the system to relieve the person of the burden of meal entry and carbohydrate estimation.

The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Such personalization may include receiving and / or determining one or more user specific dosage parameters.

The disclosed embodiments are directed to methods for dynamically adjusting the total daily insulin requirements of a user during pregnancy, based on the gestational week. An initial estimate of the adjusted total daily insulin requirement may be calculated as a multiple of the pre-pregnancy total daily insulin requirement, based on an average scale factor from a population of pregnant women suffering from Type I diabetes mellitus. An automatic drug delivery device may adjust the initial estimate of the total daily insulin requirement based on blood glucose level readings from a continuous glucose monitor during the course of the pregnancy.

A method may include delivering insulin, using an insulin pump and a controller, over a first diurnal time period based on a baseline basal insulin rate stored in memory. The controller may receive blood glucose data to control delivery of insulin via the insulin pump in amounts variable from the baseline basal insulin rate to control blood glucose levels for a person with diabetes (PWD). The method may also include modifying the baseline basal insulin rate stored in the memory for a second diurnal time period that is at least 20 hours after the first diurnal period based on an amount of insulin actually delivered during the first diurnal time period.

Disclosed herein are systems and methods for mitigating the risk of insulin stacking in automated insulin delivery systems. In AID systems configured to both automatically calculate insulin delivery based on glucose levels and receive manual programming of meal boluses configured to counteract carbohydrates in a meal, insulin stacking can result if the system automatically increases insulin delivery based on a rise in glucose levels in response to consumption of a meal and the user later programs a meal bolus for the meal. The risk of such double dosing is mitigated by the systems and methods disclosed herein by enabling the system to account for recent automated insulin increases when a meal bolus is programmed.

The invention relates to the technical field of medical equipment, and discloses a diabetic insulin infusion device which comprises a mounting shell, a medicine storage shell is fixedly mounted in the middle of the top end of the mounting shell, a containing cavity used for containing insulin is formed in the medicine storage shell, and a protective shell is detachably connected to one side of the top of the mounting shell; a driving motor is fixedly mounted on the inner side of the protective shell, a fixed seat is fixedly connected to the inner bottom wall of the capacity cavity, a movable rod is slidably connected to an inner through hole of the fixed seat, a rotating shaft is movably connected to the interior of the capacity cavity through a bearing, and a driving part is fixedly connected to the middle side of the exterior of the rotating shaft; and the inner side of the driving piece is rotationally connected with a hinge rod. Through the targeted anti-blocking design, the continuity and smoothness of insulin delivery in the infusion tube can be continuously guaranteed, abnormal blood glucose fluctuation caused by infusion interruption and the risk of hypoglycemia caused by blind supplementary infusion after blockage is removed are avoided, and the stability and accuracy of insulin infusion are remarkably improved.

An automated insulin delivery system provides an insulin injection that is computed by adding (i) the recommendation of an artificial neural network trained to mimic a constrained model predictive controller dosing rule from a neural network implementing an artificial pancreas (ii) a hypoglycemia mitigation system includeds a correction (one dose computed as the correction down to 110mg / dl based on prevailing continuous glucose monitoring and once an hour at most, unless there is a triggering BPS and G>180 mg / dl), and (iii) the current basal rate (output of the Performance Assessment System, (PAS)); that amount is then saturated by the Safety Supervision System, SSM. Finally, a priming bolus from the Bolus Priming System, BPS, is added to the total if the conditions for large glycemic excursions are detected, also saturated by SSM.

The exemplary embodiments provide an automated approach for adjusting the medicament delivery rate to the user when operating in an open loop manner (“open mode”). The approach relies upon an insulin delivery history to the user make adjustments to the medicament delivery rate in the open mode. In particular, the exemplary embodiments may look at the medicament delivery history while the medicament delivery device is operating in a closed loop manner (“closed mode”) to determine how to adjust the open mode medicament delivery rate. It is presumed that in closed mode, the control system of the medicament device has gained knowledge over time about how to control the medicament delivery rate to produce good treatment outcomes for the user. The exemplary embodiments leverage this knowledge to adjust the open mode medicament delivery rates. Medicament bolus deliveries in open mode may also be adjusted in like fashion.

Disclosed herein are techniques for blood glucose management. In one example, a processor-implemented method includes receiving an input of a target value of a first continuous glucose monitoring (CGM) metric, estimating a target value of at least a second CGM metric that corresponds to the target value of the first CGM metric, and providing the estimated target value of at least the second CGM metric to a user. In some examples, the processor-implemented method also includes determining that the estimated target value of at least the second CGM metric meets a predetermined criterion, and configuring an insulin delivery system based on the target value of the first CGM metric.

A control device for managing insulin delivery in a closed-loop system. The control device comprises a computation module. The computation module is configured to receive a target basal rate indicative of a rate of a target insulin delivery rate of an insulin pump and compute a supplemental basal rate if the target basal rate is greater than a rate threshold. The supplemental basal rate is sensibly equal to a difference between the target basal rate and the rate threshold. The control device also comprises an insulin management module. The insulin management module is configured to determine a recommendation value of a control parameter of the insulin pump. The recommendation value is based on the supplemental basal rate multiplied by a time period. The control device comprises a communication module. The communication module is configured to send the recommendation value to the insulin pump.